Fourth misoprostol product prequalified
The World Health Organisation Prequalification team have announced the prequalification of a fourth generic misoprostol 200μg product.
These tablets are manufactured by China Resources Zizhu Pharmaceutical Co. Ltd., based in Beijing, China. Misoprostol is used to prevent post-partum hemorrhage, a condition that causes one out of every four maternal deaths annually and accounts for more maternal deaths than any other individual cause.
Having a fourth misoprostol product included in the list of prequalified medicinal products is a further step in making the drug more readily available to women who need it : the list has become a vital tool for any agency or organization involved in bulk purchasing of medicines, be this at country level, or at international level.
Concept Foundation has been working closely with CR Zizhu, providing technical assistance to achieve WHO prequalification for both this misoprostol product and their mifepristone product, which was prequalified in August this year. This work was done under the auspices of the United Nations Commission on Life Saving Commodities, with general support from the David and Lucile Packard Foundation.